Radioactive antibody combo aims to stop prostate cancer spread
NCT ID NCT00859781
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This phase 2 trial tests whether a radioactive antibody called 177Lu-J591, combined with the hormone-blocking drug ketoconazole, can prevent prostate cancer from spreading in high-risk patients. The study enrolls 55 men whose PSA is rising despite hormone therapy but who have no visible metastases. The main goal is to see how many remain free of detectable spread after 18 months.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
177Lu-J591 (a radioactive antibody) and ketoconazole (a hormone-blocking drug)
What this could lead to
If this works, it could offer a new way to delay or prevent the spread of prostate cancer in high-risk patients whose PSA is rising despite hormone therapy.
What could go wrong
This is a small, early-phase trial with only 55 participants, so results may not apply to everyone. The combination therapy can cause side effects like low blood counts and fatigue.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PROSTATE CANCER are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Cedars Sinai
Los Angeles, California, 90048, United States
-
Georgetown University Medical Center
Washington D.C., District of Columbia, 20007, United States
-
Indiana University Melvin and Bren Simon Cancer Center
Indianapolis, Indiana, 46202, United States
-
The University of Kansas Cancer Center
Westwood, Kansas, 66205, United States
-
UPMC Hillman Cancer Center
Pittsburgh, Pennsylvania, 15232, United States
-
USC/Norris Comprehensive cancer center
Los Angeles, California, 90089, United States
-
University of Iowa Hospitals and Clinics
Iowa City, Iowa, 52242, United States
-
University of Utah
Salt Lake City, Utah, 84108, United States
-
Weill Cornell Medical College
New York, New York, 10021, United States